Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Rapid Therapeutic Science Laboratories, Inc. (RTSL) Long-Term Debt Issuances (2017 - 2023)

Rapid Therapeutic Science Laboratories' Long-Term Debt Issuances history spans 7 years, with the latest figure at -$50000.0 for Q2 2023.

  • For Q2 2023, Long-Term Debt Issuances fell 139.96% year-over-year to -$50000.0; the TTM value through Jun 2023 reached $224251.0, down 88.35%, while the annual FY2022 figure was $749378.0, 54.58% down from the prior year.
  • Long-Term Debt Issuances for Q2 2023 was -$50000.0 at Rapid Therapeutic Science Laboratories, down from $50000.0 in the prior quarter.
  • Across five years, Long-Term Debt Issuances topped out at $1.4 million in Q3 2021 and bottomed at -$50000.0 in Q2 2023.
  • The 5-year median for Long-Term Debt Issuances is $123563.5 (2020), against an average of $233005.6.
  • The largest annual shift saw Long-Term Debt Issuances surged 1385.15% in 2019 before it plummeted 139.96% in 2023.
  • A 5-year view of Long-Term Debt Issuances shows it stood at $300000.0 in 2019, then changed by 0.0% to $300000.0 in 2020, then soared by 366.67% to $1.4 million in 2021, then crashed by 89.29% to $150001.0 in 2022, then tumbled by 133.33% to -$50000.0 in 2023.
  • Per Business Quant, the three most recent readings for RTSL's Long-Term Debt Issuances are -$50000.0 (Q2 2023), $50000.0 (Q1 2023), and $150001.0 (Q4 2022).